HSD17B13 : Inhibitors Wikipedia, the free encyclopedia

HSD17B13

Protein-coding gene in the species Homo sapiens

HSD17B13

Identifiers

Aliases

HSD17B13, NIIL497, SCDR9, SDR16C3, HMFN0376, hydroxysteroid (17-beta) dehydrogenase 13, hydroxysteroid 17-beta dehydrogenase 13

External IDs

OMIM: 612127; MGI: 2140804; HomoloGene: 71549; GeneCards: HSD17B13; OMA:HSD17B13 - orthologs

Gene location (Human)

Chr.	Chromosome 4 (human)^[1]

Band	4q22.1	Start	87,303,789 bp^[1]
Band	4q22.1	End	87,322,886 bp^[1]

Gene location (Mouse)

Chr.	Chromosome 5 (mouse)^[2]

Band	5\|5 E5	Start	104,103,306 bp^[2]
Band	5\|5 E5	End	104,125,276 bp^[2]

RNA expression pattern

Bgee

Human

Mouse (ortholog)

Top expressed in

liver

right lobe of liver

olfactory zone of nasal mucosa

vagina

subcutaneous adipose tissue

lactiferous gland

myometrium

ectocervix

skin of leg

body of uterus

Top expressed in

left lobe of liver

epithelium of small intestine

duodenum

zygote

secondary oocyte

ileum

migratory enteric neural crest cell

primary oocyte

islet of Langerhans

jejunum

More reference expression data

BioGPS

n/a

Gene ontology
Molecular function	oxidoreductase activity molecular function steroid dehydrogenase activity
Cellular component	extracellular region lipid droplet cytosol cellular component
Biological process	positive regulation of lipid biosynthetic process lipid droplet organization biological process
Sources:Amigo / QuickGO

Orthologs

Species

Human

Mouse

Entrez


345275


243168

Ensembl


ENSG00000170509


ENSMUSG00000034528

UniProt


Q7Z5P4


Q8VCR2

RefSeq (mRNA)


NM_178135 NM_001136230


NM_001163486 NM_198030

RefSeq (protein)


NP_001129702 NP_835236


NP_001156958 NP_932147

Location (UCSC)

Chr 4: 87.3 – 87.32 Mb

Chr 5: 104.1 – 104.13 Mb

PubMed search

^[3]

^[4]

Wikidata

View/Edit Human

View/Edit Mouse

17β-Hydroxysteroid dehydrogenase type 13 also known as 17β-HSD type 13 is an enzyme that in humans is encoded by the HSD17B13 gene.^[5]^[6]

17β-HSD13 is significantly up-regulated in the liver of patients with non-alcoholic fatty liver disease (NAFLD) and enhances lipogenesis.^[7]

Inhibitors

In 2023 the first potent and selective HSD17B13 inhibitor, BI-3231, was reported.^[8] The inhibitor meets the quality criteria of a 'Donated Chemical Probe' as defined by the Structural Genomics Consortium.^[9]

References

^ ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000170509 – Ensembl, May 2017
^ ^a ^b ^c GRCm38: Ensembl release 89: ENSMUSG00000034528 – Ensembl, May 2017
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Zhu YS, Imperato-McGinley JL (9 November 2016). "4.02: Disorders of Sexual Development in Males: Molecular Genetics, Epigenetics, Gender Identity, and Cognition". In Lightman S (ed.). Hormones, Brain and Behavior. Vol. 4: Clinical Important Effects of Hormones on Brain and Behavior. Elsevier Science. p. 69. ISBN 978-0-12-803608-2.
^ Zanders ED (9 November 2015). Human Drug Targets: A Compendium for Pharmaceutical Discovery. John Wiley & Sons. pp. 257–. ISBN 978-1-118-84985-9.
^ Su W, Wang Y, Jia X, Wu W, Li L, Tian X, Li S, Wang C, Xu H, Cao J, Han Q, Xu S, Chen Y, Zhong Y, Zhang X, Liu P, Gustafsson JÅ, Guan Y (2014). "Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease". Proceedings of the National Academy of Sciences of the United States of America. 111 (31): 11437–42. Bibcode:2014PNAS..11111437S. doi:10.1073/pnas.1410741111. PMC 4128098. PMID 25028495.
^ Thamm, Sven; Willwacher, Marina K.; Aspnes, Gary E.; et al. (2023). "Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science". Journal of Medicinal Chemistry. 66 (4): 2832–2850. doi:10.1021/acs.jmedchem.2c01884. PMC 9969402. PMID 36727857.
^ "Donated Chemical Probes". thesgc.org. Retrieved July 31, 2023.